

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Chow et al. I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an 09/815,362 Serial No.: envelope addressed to: Box Petition to Inventorship, Commissioner for Patents, Washington, March 21, 2001 Filed: D.C. 20231 on: COMPOUNDS AND METHOD OF For: TREATMENT HAVING AGONIST-LIKE ACTIVITY SELECTIVE AT ALPHA 2B OR 2B/2C ADRENERGIC RECEPTORS Deposit Floyd D. Higel Examiner: Art Unit: 1626

## PETITION FOR CORRECTION OF INVENTORSHIP

Assistant Commissioner for Patents Washington, D.C. 20231

Dear Sir:

Applicants hereby petition the Commissioner pursuant to 37 CFR 1.48(a) to correct the inventorship in the above-referenced patent application. Through error, inventor Dario M. Gomez was not named as a joint inventor when this continuation patent application was filed. This error was made by the undersigned without deceptive intent in the haste to file the present application; such haste was exacerbated by the fact the undersigned was simultaneously working without an experienced assistant at the time, a lack that has thankfully since been cured.

Accordingly, Applicants petition the Commissioner to amend the application to set forth the actual inventors. Accompanying this petition is 1) a Statement of Dario M. Gomez in support of the correction of inventorship, 2) a Declaration by the actual inventors as required by 37 CFR §1.63, and 3) the written consent of the assignee, Allergan Sales, Inc., for such correction of inventorship.

Serial No. 09/815,362 Docket No. 17243CIP3(AP)

Kindly use Deposit Account 01-0885 for the payment of the petition fee and any other cost that may be due as a result of this communication.

2

Respectfully submitted,

Telephone: (714) 246-4920 Facsimile: (714) 246-4249

Carlos A. Fisher-T2-7H Registration No. 36,510

Attorney of Record ALLERGAN, INC.

Legal Department

2525 Dupont Drive Irvine, CA. 92612